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ABSTRACT
Recent studies report that nuclear factor-erythroid-2-related factor 2 (Nrf2) facilitates tumor pro-
gression through metabolic reprogramming in cancer cells. However, the molecular mechanism
underlying the oncogenic functions of Nrf2 is not yet well understood. Some of the pentose
phosphate pathway (PPP) enzymes are considered to play a role in the cancer progression. The
present study was intended to explore the potential role of phosphogluconate dehydrogenase
(PGD), one of the PPP enzymes, in the proliferation and migration of human hepatoma HepG2
cells. Genetic ablation of Nrf2 attenuated the expression of PGD at both transcriptional and
translational levels. Notably, Nrf2 regulates the transcription of PGD through direct binding to
the antioxidant response element in its promoter region. Nrf2 overexpression in HepG2 cells led
to increased proliferation, survival, and migration, and these events were suppressed by silencing
PGD. Interestingly, knockdown of the gene encoding this enzyme not only attenuated the prolif-
eration and clonogenicity of HepG2 cells but also downregulated the expression of Nrf2. Thus,
there seems to exist a positive feedback loop between Nrf2 and PGD which is exploited by
hepatoma cells for their proliferation and survival. Treatment of HepG2 cells with ribulose-5-
phosphate, a catalytic product of PGD, gave rise to a concentration-dependent upregulation of
Nrf2. Collectively, the current study shows that Nrf2 promotes hepatoma cell growth and pro-
gression, partly through induction of PGD transcription.
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Nuclear factor-erythroid-2-related factor 2 (Nrf2) is a
transcription factorinvolved in the cellular defense
against oxidative stress and carcinogenic insults by
inducing the expression of genes responsible for
encoding antioxidant/ carcinogen detoxifying enzymes
and related cytoprotective proteins [1,2]. Due to such
roles, Nrf2 has been considered as one of the prime tar-
gets for cancer chemoprevention [3]. However, recent
studies have shown that cancer cells also harness Nrf2
for their survival advantage, invasiveness, and chemore-
sistance [4]. Many different types of cancer have muta-
tions in Nrf2 or its inhibitor Kelch-like ECH-associated
protein 1 (Keap1), which result in constitutive overacti-
vation of Nrf2 signaling [4–6]. However, the molecular
mechanisms by which Nrf2 promotes cancer plasticity
have not yet been fully elucidated. Nrf2 upregulates
transcription of target genes by binding to the antioxi-
dant response element (ARE) present in the 50-upstream
of their promoter region [7]. ARE, also known as electro-
phile response element (EpRE), has a core sequence of
50-TGAG/CNNNGC-30 [8]. An oligonucleotide microarray
analysis identified Nrf2-regulated genes, and some of
them were found to encode a series of enzymes
involved in intermediary metabolism [9].
Metabolic reprogramming is one of the hallmarks of
cancer defined by Hanahan and Weinberg in their
updated seminal review paper published in 2011 [10]. A
growing body of evidence supports that metabolic
reprogramming is necessary to support cancer cell
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proliferation and survival [11–13]. The Warburg effect
describes the paradoxical phenomenon (the so-called
“aerobic glycolysis”) in which cancer cells, even in the
presence of oxygen, prefer glycolysis to the energetic-
ally more efficient mitochondrial oxidative phosphoryl-
ation [14]. In addition, this shift provides cancer cells
with important macromolecular precursors needed to
support their rapid proliferation and growth [15].
Phosphogluconate dehydrogenase (PGD) is one of
the key enzymes in the pentose phosphate pathway
(PPP) which converts 6-phosphogluconate to ribulose-
5-phosphate (Ru-5-P) through oxidative decarboxyl-
ation. During this process, one molecule of the reduced
form of nicotinamide adenine dinucleotide phosphate
(NADPH) is also produced. NADPH is essential for both
cellular defense against oxidative stress and for reduc-
tive biosynthesis, such as lipogenesis [16]. Ru-5-P is con-
verted by ribose-5-phosphate isomerase to ribose-5-
phosphate which serves as a precursor of nucleotide
biosynthesis [17]. Increased expression/activity of PGD
has been reported in several malignancies including
lung cancer [18,19], thyroid cancer [20], and cervical
intraepithelial neoplasia [21]. Suppression of PGD was
shown to attenuate cancer cell proliferation through
reduction of lipogenesis and RNA biosynthesis [22].
Likewise, PGD knockdown suppresses growth of lung
cancer cells by inducing senescence [19]. Additionally,
PGD was found to be necessary for c-Met phosphoryl-
ation which was associated with invasiveness of lung
cancer cells [18].
In this study, the role of PGD in cancer cell prolifer-
ation and migration induced by Nrf2 was investigated
in human hepatoma HepG2 cells. Here we report that
Nrf2 induces PGD transcription by directly binding to
the ARE present in the promoter region of this gene.
Materials and methods
Materials
Primary antibodies against PGD and Keap1 were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA).
The primary antibody for heme oxygenase-1 (HO-1) was
bought from Enzo Life Sciences (Farmingdale, NY). The
primary antibody for actin was obtained from AbClon
Inc. (Seoul, South Korea). Antibodies against Nrf2 and
p62 were purchased from Abcam (Cambridge, MA). The
secondary anti-rabbit IgG, horseradish peroxidase-
linked antibody was bought from Cell Signalling
Technology (Beverly, MA). Ru-5-P was purchased from
Sigma-Aldrich Co. (St. Louis, MO).
Cell culture
HepG2 cells were obtained from American Type Culture
Collection (Manassas, VA) and cultured in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented
with 10% v/v fetal bovine serum (FBS) and 100 units/ml
antibiotic–antimycotic (Thermo Fisher Scientific;
Rockford, IL).
siRNA transient transfection
HepG2 cells were reverse transfected with correspond-
ing siRNA. The following siRNAs were used for transfec-
tion: human negative-siRNA (50-CCUCGUG CCGUUCCA
UCAGGUAGUU-30), siNrf2 (50-AAGAGUAUGA GCUGGAA
AAACTT-30, Invitrogen), siPGD (50-CUCACACCUAUGAAC
UCUU(dTdT)-30, Bioneer). siRNA was diluted in 1ml of
Opti-MEM and vortex-mixed. LipofectamineVR RNAiMAX
(Invitrogen;Carlsbad, CA) reagent was then added to
the mixture followed by incubation for at least 20min
prior to addition to the freshly seeded cells in media
without antibiotics and FBS. After 24 h transfection, the
medium was changed to full media (with 10% FBS and
1% antibiotic–antimycotic). After incubation for add-
itional 48 h, cells were harvested for either mRNA
extraction or protein analysis.
Plasmid transfection
HepG2 cells were transfected with pcDNA3 plasmid
carrying cDNA for Nrf2 and a Myc tag (Plasmid #21555
from Addgene; Cambridge, UK) using LipofectamineVR 2000
(Invitrogen; Carlsbad, CA) reagent. The transfection was
done according to the manufacturer’s instructions. A
pCMV3-N-Myc plasmid vector carrying cDNA for PGD
(HG10393-NM from Sino Biological; Wayne, PA) was used
for the overexpression of PGD. An empty vector (pcDNA
3.1 plasmid) was used as a control.
Thiazolyl blue tetrazolium bromide (MTT) assay
Transfected cells incubated for 72 h were trypsinized
and seeded at a density of 3.5 103 cells per well in a
96-well plate. After 48 h of incubation, the medium was
replaced by 0.5mg/ml of MTT in DMEM. After incuba-
tion for 3 h, the supernatant was removed, and the for-
mazan crystals formed was dissolved in dimethyl
sulfoxide (DMSO). The absorbance at 570 nm was read
using a micro-plate reader (Bio-Rad Laboratories;
Hercules, CA).
2 A. J. ONG ET AL.
Colony forming assay
The cells were transfected with the indicated expression
vectors or siRNAs in a 60mm plate as described above.
After 72 h of transfection, the cells were washed,
counted and plated at a density of 500 cells per well in
a 6-well plate. Cells were further cultured for 10 days in
standard conditions. The plates were washed with
phosphate-buffered saline (PBS), fixed with chilled
methanol for 10min, and stained with 0.1% crystal vio-
let solution. Plates were imaged by using the LAS-4000
image reader (Fuji film), and colonies having more than
50 cells were counted.
Migration assay
Two-well Culture-Inserts (IbidiVR ) were attached to 12-
well plates. HepG2 cells transfected with appropriate
vectors were seeded at a density of 2.5 104 cells on
each well of the Culture-Insert. After incubation for
24 h, the silicon inserts were removed, and cells were
photographed under the microscope. The cells were
again photographed after 48 h to assess the closure of
the wound gap.
Western blot analysis
Standard SDS-PAGE and Western blotting procedures
were used to analyze the expression of various pro-
teins. Protein samples were prepared using SDS sam-
ple buffer (50mM Tris-HCl, pH 6.8, 2% SDS, 10%
glycerol, and 0.02% bromophenol blue) . All proteins
were visualized using a horseradish peroxidase-conju-
gated secondary antibody and Amersham ECLTM
Western Blotting Detection Reagents (GE Healthcare
Life Sciences; Marlborough, MA).
Reverse transcription polymerase chain reaction
(RT-PCR)
Total RNA was isolated from HepG2 cells using TRIzolVR
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s protocol. RT-PCR was performed following stand-
ard procedures. One microgram of the extracted RNA
for each sample was reverse transcribed to complemen-
tary DNA with M-MLV (Moloney Murine Leukemia Virus)
reverse transcriptase at 42 C for 50min and 72 C for
15min. One mL of cDNA was used for further amplifica-
tion in sequential reactions using SolgTM 2X Taq PCR
Smart mix 1 (SolGent, Seoul, Korea). The sequences of
the primer pairs used are as follows (forward and
reverse, respectively): PGD, 50-GCTCTTCGGTTCTG
CTCTGT-30 and 50-CCAGTTCCCACTTTTGCAGC-30; Nrf2,
50-TTCAAAGCGTCCGAACTCCA-30 and 50-AATGTCTGCGC
CAAAAGCTG-30; Keap1, 50-CAGAGGTGGTGGTGTTGCTTA-
30 and 50-AGCTCGTTCATGATGCCAAAG-30; HO-1, 50-
CCAGGCAGAGAATGCTGAGTTC-30 and 50-TCTTCTATCA
CCCTCTGCCTGAC-30; GCLC, 50-ACCA GGACAGCC-30 and
50-ATG ATG CCA AAG-30; GAPDH, 50-ACCACAGTCCAT
GCCATCAC-30 and 50-TCCACCACCCTGTTGCTGTA-30.
Immunocytochemical analysis
HepG2 cells transfected with either siControl or siPGD
RNA were plated on 8-well chamber slides at a density
of 2 104 per well. After fixation with 4% formaldehyde
for 15min at 37 C, the cells were rinsed with PBST (PBS
containing 0.1% Tween-20) and incubated with 0.1%
Triton X-100 in PBS for 5min. Then, the cells were
washed and blocked with 0.05% Triton X-100 in PBS
containing 5% bovine serum albumin (BSA) at room
temperature for 1 h. The cells were then washed with
PBST and incubated with the Nrf2 primary antibody
overnight at 4 C. After washing with PBST, the cells
were incubated with FITC-conjugated anti-rabbit IgG
secondary antibody in PBST containing 5% BSA at room
temperature for 1 h. After washing with PBST, cells were
stained with 40,6-diamidino-2-phenylindole (DAPI) in
PBS for 15min. The cells were then washed with PBST
and examined under a fluorescent microscope.
Chromatin immunoprecipitation (ChIP) assay
For the ChIP assay, cells were washed with PBS and
cross-linked with a 1% formaldehyde solution for
30min at room temperature. The crosslinking reaction
was stopped by the addition of glycine to 125mM final
concentration. Cell lysates were sonicated to generate
DNA fragments with the average size of 300–600 base
pairs. This was followed by immunoprecipitation with
indicated antibodies, which were bound to Protein
Agarose A/G (Santa Cruz, CA) by an overnight incuba-
tion prior to use. Bound DNA fragments were eluted
and purified using the BiomedicVR Plasmid DNA
Miniprep Kit (Seoul, South Korea). The collected DNA
was then amplified by PCR. The primers for the PGD-
ARE region are 50-CCCCCTCTAACAGGAAGGGT-30 and 50-
ACCACTTTTTCCCCCATAGACAA-30.
Statistical analysis
Results were expressed as the means ± SEM of at least
three independent experiments. The statistical signifi-
cance of the difference between two groups was eval-
uated using Student’s t test. Analysis was performed
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using IBM SPSS Statistics (Version 23, IBM SPSS
Statistics, Armonk, NY). Statistical significance was
accepted at p< 0.05, unless otherwise indicated.
Results
Nrf2 directly regulates PGD transcription in
HepG2 cells
Nrf2 has been shown to regulate the expression of
metabolic enzymes in various cancer cell lines [9,23].
Knockdown of Nrf2 with siRNA resulted in the inhibition
of PGD mRNA expression (Figure 1(A)) and its protein
product (Figure 1(B)). Under the same experimental
conditions, expression of HO-1, a well-known target of
Nrf2 [24], was also significantly suppressed (Figure 1(B)).
To explore whether Nrf2 is associated with the stability
of PGD mRNA, HepG2 cells were treated with the tran-
scription inhibitor actinomycin D (10lg/ml). However,
the levels of remaining PGD mRNA did not significantly
differ between siControl and siNrf2 transfected cells
(Figure 1(C)), suggesting that Nrf2 may induce PGD
expression through a transcriptional rather than post-
transcriptional mechanism.
Upon activation, the heterodimer Nrf2 bound to a
small Maf protein interacts with ARE in the regulatory
region of its target genes [25,26]. Nrf2 has been found
to directly bind to the ARE-region of PGD in A549 cells
[23]. The promoter region of PGD harbors an Nrf2 bind-
ing site (Figure 1(D)). To confirm Nrf2 interaction with
the ARE consensus sequence in the PGD regulatory
region in HepG2 cells, a ChIP assay was performed. As
Figure 1. Nrf2 regulates the transcription of PGD by binding to the ARE in the promoter region. HepG2 cells were transfected
with either a non-targeting siRNA or siNrf2 RNA and incubated for 72 h. (A) The expression of PGD as well as Nrf2 was deter-
mined by PCR. Relative mRNA levels were normalized to GAPDH. (B) Total cell lysates were subjected to Western blot analysis.
Band intensities were normalized to actin. (C) Transfected cells were treated with actinomycin D (Act; 10 mg/ml) for indicated
time periods. Mean band intensities normalized to GAPDH were divided by the 0 h control multiplied by 100. (D) The PGD gene
promoter sequence harboring the ARE consensus motif for Nrf2 binding. The nucleotides of the ARE consensus motif
(GCNNNNTCA) are indicated in bold. (E) A ChIP assay was performed on HepG2 cells to detect the binding of Nrf2 to the ARE in
the promoter region of PGD. Protein-DNA complexes were stabilized by crosslinking. The cell lysate was immunoprecipitated with
a Nrf2 antibody. Reverse crosslinking was performed, and DNA was extracted and purified. DNA samples were amplified by PCR.
For all panels, each bar shows the mean± SEM of three independent experiments. The p values were determined by independent
t-test (, 0.05> p> 0.01; , 0.01> p> 0.001; , 0.001> p versus control).
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illustrated in Figure 1(E), Nrf2 binds to ARE present in
the PGD gene promoter. This finding is consistent with
that reported by Mitsuishi and colleagues who identi-
fied PGD as one of the Nrf2 target genes [23].
Nrf2 promotes proliferation and migration of
HepG2 cells
Previous studies have shown that Nrf2 promotes prolif-
eration and survival of several types of cancer cells
[4–6,23,24,27,28]. To validate this in HepG2 cells, the
MTT assay and the clonogenic assay were performed.
The silencing of Nrf2 by siRNA transfection attenuated
proliferation (Figure 2(A)) and survival (Figure 2(B)) of
HepG2 cells. Further, Nrf2 gene knockdown also
dampened the migrative capability of these cells
(Figure 2(C)). In contrast, Nrf2 overexpression with
pcDNA3-Nrf2-Myc plasmid provoked opposite effects
on all these events (Figure 2(D, E, and F)).
PGD is important for proliferation of HepG2 cells
Rapid proliferation of cancer cells requires not only ATP
but also building blocks necessary for the synthesis of
nucleotides, fatty acids and amino acids [11]. Ru-5-P, a
byproduct of PGD, is utilized in nucleic acid biosyn-
thesis [22]. HepG2 cells were transfected with siControl
RNA or siPGD RNA, and cell proliferation and survival
were assessed. PGD silencing resulted in a decreased
viability (Figure 3(A)) and clonogenicity (Figure 3(B)) of
Figure 2. Nrf2 mediates proliferation and survival of HepG2 cells. (A and B) HepG2 cells were transfected with either a non-tar-
geting siRNA or siNrf2 RNA. (A) After 48 h of incubation, cells were seeded in a 96-well plate. Cell viability was measured by the
MTT assay 48 h after seeding. (B) After 48 h of incubation, cells were seeded in a 6-well plate. Colonies formed were counted
after incubation for 10 days. (C) Cells were seeded into the two wells of an insert. After 24 h of incubation, the insert was
removed and the cells were incubated for additional 48 h. The wound gap was measured under a light microscope as described
in Materials and methods. (D and E) HepG2 cells were transfected with pcDNA3 (Control) or pcDNA3-Nrf2-Myc (Nrf2-expressing
plasmid). After 24 h of incubation, cells were seeded in a 96-well plate. Cell viability was measured by the MTT assay 48 h after
seeding (D). The remaining proportion of cells was seeded in a 6-well plate. Colonies were counted after incubation for 10 days
(E). (F) The migrative capability of HepG2 cells transfected with an empty or an Nrf2 overexpressing vector was measured as
described in legend to (C). For all panels, each bar shows the mean of three independent experiments ± SEM. The p values were
determined by independent t-test (, 0.05> p> 0.01; , 0.01> p> 0.001 versus control).
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HepG2 cells whereas overexpression of PGD enhanced
cell viability (Figure 3(C)) and colony formation
(Figure 3(D)).
PGD mediates Nrf2-induced HepG2 cell
proliferation and survival
HepG2 cells transfected with pcDNA 3.1 (Mock) or
pcDNA 3.1-Nrf2-Myc plasmid (Nrf2 plasmid) were co-
transfected with either siControl or siPGD RNA. As
shown in Figure 3(E), both Nrf2 plasmid and siControl
RNA co-transfected cells had an increased clonogenicty
compared to the cells transfected with mock vector and
siControl RNA. However, this was repressed by the
knockdown of PGD in the Nrf2 overexpressing cells
(Figure 3(E)). Given that the increase in cell proliferation
as a consequence of Nrf2 overexpression was hindered
by silencing PGD, this finding suggests that PGD can
contribute to the Nrf2-mediated proliferation and sur-
vival of HepG2 cells.
PGD regulates Nrf2 via a positive feedback loop
A previous study provided evidence that glucose-6-
phosphate dehydrogenase, the first enzyme in the PPP,
and NADPH are important in the Nrf2-induced expres-
sion of antioxidant proteins, such as HO-1 and glutathi-
one reductase [29]. Since PGD is also a part of the PPP,
we examined its effect on expression of Nrf2 and its tar-
get proteins. Notably, silencing of PGD dampened the
endogenous expression of Nrf2 (Figure 4(A)) in HepG2
cells. In addition, the ectopic expression of Nrf2 using
the mammalian expression vector, pcDNA3 was also
attenuated upon siPGD RNA co-transfection (Figure
Figure 3. PGD is involved in HepG2 cell proliferation. (A and B) HepG2 cells were transfected with either a non-targeting siRNA
or siPGD RNA. After 48 h of incubation, cells were seeded in a 96-well plate and a 6-well plate to measure the viability and clo-
nogenicity, respectively after additional incubation for 48 h and 10 days . (C and D) HepG2 cells transfected with pcDNA3
(Control) or N-Myc-PGD plasmid. The viability and colony forming ability of cells were determined by the MTT (C) and the clono-
genicity (D) assays, respectively as described above. (E) HepG2 cells were transfected with either a non-targeting siRNA or siPGD
RNA and incubated for 24 h. Each group was then subsequently co-transfected with either pcDNA3 (Control) or pcDNA3-Nrf2-Myc
(Nrf2-expressing plasmid). After 48 h of incubation, cells were seeded in a 6-well plate. Colonies were counted after 10 days of
incubation. For all panels, each bar shows the mean± SEM of three independent experiments. The p values were determined by
independent t-test (, 0.05> p> 0.01; , 0.01> p> 0.001; , 0.001> p versus control).
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4(B)). Furthermore, immunocytochemical analysis
showed that genetic ablation of PGD decreased the
nuclear localization of Nrf2 (Figure 4(C)). The expression
of HO-1 and GCLC, two representative Nrf2 target mole-
cules, was also blunted by PGD silencing at both tran-
scriptional (Figure 4(D)) and translational (Figure
4(E)) levels.
PGD promotes the degradation of Keap1, a
negative regulator of Nrf2
Keap1 is a negative regulator of Nrf2 [1–3,30]. It inter-
acts with the N-terminal Neh2 domain of Nrf2 to facili-
tate proteolytic degradation of this transcription factor
[1–3,31]. PGD silencing did not affect the mRNA expres-
sion (Figure 5(A)), but increased the protein expression
of Keap1 (Figure 5(B)). Thus, it is likely that PGD may
promote degradation of Keap1 protein primarily via
post-translational mechanisms. The sequestosome 1
(p62/SQSTM) is a scaffold protein that binds to polyubi-
quitinated proteins and targets protein aggregates and
damaged organelles for degradation via the autophagy
pathway [32]. Previous studies have shown the degrad-
ation of Keap1 through p62-dependent autophagy
[28,32]. The p62-mediated sequestration of Keap1 into
autophagosomes resulted in a decrease in Nrf2 ubiqui-
tination and consequently an increase in Nrf2 stability
[33]. Of note, knockdown of PGD also reduced p62 pro-
tein levels (Figure 5(C)). Likewise, a pharmacologic
inhibition of PGD with Physcion [22] suppressed p62
expression with concurrent restoration of Keap1 accu-
mulation (Figure 5(D)), suggesting that p62-dependent
degradation of Keap1 may account for PGD-induced
stabilization of Nrf2.
PGD converts 6-phosphogluconate to Ru-5-P which
then enters the non-oxidative arm of the PPP and
Figure 4. PGD regulates Nrf2 expression in HepG2 cells. The cells were transfected with either a non-targeting siRNA or siPGD
RNA and incubated for 72 h. (A) The protein level of Nrf2 in total cell lysates was determined by the Western blot analysis. (B)
Cells transfected with pcDNA 3.1-Nrf2-Myc were co-transfected with either non-targeting siRNA or siPGD. Total lysates were sub-
jected to Western blot analysis. Band intensities were normalized to actin. (C) Cells were fixed, and the localization of Nrf2 was
visualized by immunofluorescence staining as described in Materials and methods. Scale bar: 10 mm. (D) mRNA levels of Nrf2 tar-
get genes were measured by RT-PCR. Band intensities were normalized to GAPDH. (E) Protein levels of Nrf2 target genes were
measured by Western blot analysis. Band intensities were normalized to actin. For all panels, each bar shows the mean± SEM of
three independent experiments. The p values were determined by independent t-test (, 0.05> p> 0.01; , 0.01> p> 0.001
versus control).
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proceeds to purine biosynthesis [34]. To determine
whether this particular metabolite could mediate the
PGD-induced Nrf2 accumulation, HepG2 cells were
treated directly with increasing concentrations (400,
600, and 800 mM) of Ru-5-P for 24 h. Ru-5-P treatment
increased expression of Nrf2 in a concentration-
dependent manner (Figure 5(E)).
Discussion
Nrf2 functions as a master regulator of antioxidant
response and hence is a protector of oxidative stress
and other environmental insults [1,2,35]. Damage to
DNA, proteins, or lipids due to oxidative stress has been
linked to inflammation and cancer [36]. Nrf2-knockout
mice were found to be more susceptible to experimen-
tally induced carcinogenesis [37,38]. Furthermore, sensi-
tivity to the chemoprotective and chemopreventive
agents was markedly diminished in Nrf2 knockout mice
[39,40]. However, recent studies have revealed an
opposite effect of Nrf2 in cancer. Mutations to either
Nrf2 or its regulatory protein, Keap1 cause aberrant
overactivation of this transcription factor in several
malignancies, such as esophageal [41], skin [41], renal
[42], lung [43,44], gastric [44], colorectal [44], and liver
[44,45] cancer. Nrf2 confers optimal reducing power on
cancer cells to promote their growth and survival [46].
Nonetheless, the function of Nrf2, either cytoprotective
[1–3,9,25,26,35–40,47–49] or oncogenic [4–6,23,24,
27,28,41–46,50–52], is still controversial. Thus, there is a
need to conduct additional research in order to more
accurately predict the function as well as regulation of
Nrf2 in each step of the multi-stage carcinogenesis. In
addition, identification and characterization of the tar-
get genes of Nrf2 are needed in order to better under-
stand its differential roles in carcinogenesis.
There are multiple lines of compelling evidence sup-
porting that cancer is a metabolic disease [53].
Figure 5. PGD promotes the degradation of Keap1 protein. (A to C) HepG2 cells were transfected with either non-targeting
siRNA or siPGD RNA. (A) The expression of Keap1 mRNA was determined by RT-PCR. Relative mRNA levels were normalized to
GAPDH. (B and C) Total cell lysates were subjected to Western blot analysis of Keap1 (B) and p62 (C). The band intensities of
both proteins were normalized to actin. (D and E) HepG2 cells were treated with indicated concentrations of Physcion or Ru-5-P
for 24 h. The expression levels of p62, Keap1 (D) and Nrf2 (E) were measured by Western blot analysis. For all panels, each bar
shows the mean± SEM of three independent experiments. The p values were determined by independent t-test (,
0.05> p> 0.01; , 0.01> p> 0.001; , 0.001> p versus control). ns: not significant.
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Metabolic reprogramming in cancer cells supports bio-
energetics and the macromolecular synthesis required
for their proliferation and survival. This is achieved
through activation of distinct signal transduction path-
ways and reorganization of transcriptional network
[10–16,54]. The high catalytic activity of PGD has been
associated with poor relapse-free survival times in
breast cancer [55]. Elevated PGD expression levels also
correlate with an advancing stage of lung carcinoma
[18]. On the other hand, cancer cell proliferation was
found to be inhibited upon PGD silencing [18,19]. We
have previously reported the elevated expression of
PGD and some other PPP-related genes in the chem-
ically induced hepatocarcinogenesis [56]. Our present
study demonstrates that Nrf2 regulates PGD expression
by binding to the ARE located in the regulatory region
of PGD in cultured human hepatoma cells. This finding
is consistent with the result of a previous study done
with lung cancer cells [23].
Some of Nrf2 target proteins have been shown to
take part in cancer cell proliferation and survival. HO-1,
for instance, was shown to be involved in the metasta-
sis [57], invasion [58], and resistance to apoptosis [59]
in various cancer types [reviewed in 45 and more refer-
ences therein]. Similarly, NAD(P)H:quinone oxidoreduc-
tase is found to be elevated in several solid tumors
[60,61], and plays a role in the growth and survival of
tumors [62–64]. In addition, higher protein levels of
GCLC were detected in colorectal tumor tissue than in
adjacent normal tissue [65], and this was implicated in
the development of tamoxifen-resistant breast cancer
[66]. Unlike these Nrf2-regulated antioxidant enzymes,
there is paucity of data describing the signals related to
PGD as a modulator of the tumorigenic processes medi-
ated by Nrf2. The present study provides convincing
evidence supporting the involvement of PGD in Nrf2-
induced proliferation in human hepatoma cells.
Keap1 is a negative regulator of Nrf2 [1-3,30]. In
normal conditions, Keap1 sequesters Nrf2 in the cyto-
plasm, thereby inhibiting its translocation to the
nucleus [1–3,30,31]. It also facilitates the degradation
of Nrf2 by serving as an adaptor between Nrf2 and
the Cullin3-based E3-ligase ubiquitylation complex
[67]. Electrophiles, ROS, and reacrive nitrogen species
can modify the reactive ’sensor’ cysteine residues of
Keap1, leading to its inactivation [2,7,68].
Consequently, Nrf2 is stabilized, and translocates to
the nucleus where it induces the transcription of
numerous cytoprotective genes through binding to
ARE/EpRE located in their promoter region [8].
Besides this canonical pathway, the ubiquitin binding
autophagic adaptor protein p62 interacts with the
Nrf2-binding site (Kelch domain) of Keap1, thereby
protecting Nrf2 from proteasome degradation [33,69].
In hepatocytes, one mechanism underlying Keap1
degradation involves p62-dependent autophagy [32].
In this study, we have shown that genetic or pharma-
cologic inhibition of PGD enhanced Keap1 expression
Figure 6. A schematic representation of the proposed positive feedback loop between Nrf2 and PGD. Nrf2 binds to the ARE con-
sensus sequence present in the PGD regulatory region, thereby promoting its transcription in HepG2 cells. The increased PGD
expression leads to stimulation of hepatoma cell proliferation, survival and migration. Moreover, the increase in the accumulation
of PGD product Ru-5-P induces the degradation of Keap1 through p62 upregulation to create a positive feedback loop between
PGD and Nrf2.
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levels with concomitant decreases in p62 accumula-
tion. We speculate that p62-dependent autophagic
degradation of Keap1 is likely to be involved in the
regulation of Nrf2 by PGD.
Oncometabolites are endogenous substances whose
abnormal accumulation contributes to the growth and
metastasis of tumors [70]. Numerous oncometabolites
have already been identified, and some of them play a
role in the control of cell division processes [71–73].
PGD activity produces Ru-5-P and NADPH as byprod-
ucts. Interestingly, Ru-5-P was found to inhibit AMPK
activation and to activate lipogenesis through disrup-
tion of the active LKB1 complex [22]. In leukemia cells,
targeting PGD was proven to be selective and non-toxic
to normal cells [22]. We found that PGD, as a Nrf2 target
gene, upregulates Nrf2 expression, and hence com-
prises a positive feedback loop with Nrf2. This opens an
exciting possibility of attenuating Nrf2 signaling by tar-
geting PGD in cancer cells, especially those which
exhibit chemoresistance due to Nrf2 overactivation.
In summary, Nrf2 regulates the expression of PGD by
directly binding to the ARE in its regulatory region. The
upregulation of PGD by Nrf2 plays an important role in
Nrf2-mediated tumor plasticity through stimulation of
cell proliferation, survival, and migration (Figure 6).
Taken together, these results suggest PGD as a poten-
tial target in inhibiting growth and progression of hepa-
tocellular carcinoma with hyperactivated Nrf2 signaling.
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